【摘要】 目的观察吉西他滨联合替吉奥方案对比吉西他滨单药方案三线治疗晚期非小细胞肺癌的疗效及安全性。方法收集我院2012年6月~2014年6月进行三线治疗的晚期非小细胞肺癌患者68例,其中38例接受吉西他滨联合替吉奥化疗,30例接受吉西他滨单药化疗。采用RE-CIST 1.1版标准评价化疗有效率,采用美国国立癌症研究所毒性判定标准(NCI-CTCAE)4.0评价毒性反应。结果吉西他滨联合替吉奥组的有效率、中位无进展生存时间和总生存时间均高于吉西他滨单药组。联合化疗组骨髓抑制、胃肠道反应、口腔黏膜炎及疲乏发生率较单药组高,但主要为I~II级毒性反应。结论吉西他滨联合替吉奥三线治疗晚期非小细胞肺癌优于吉西他滨单药,耐受性良好,可作为晚期非小细胞肺癌三线治疗的选择。更多还原

【Abstract】 Objective To observe curative effects and safety of gemcitabine combined with Tegafur Gimeracil Oteracil Potassium compared with single Gemcitabine third-line in treatment of advanced non-small cell lung cancer. Methods 68 patients with advanced non-small cell lung cancer who received third-line treatment in our hospital from June 2012 to June 2014 were selected. Among whom, 38 patients were given gemcitabine combined with Tegafur Gimeracil Oteracil Potassium for treatment while other 30 patients were given gemcitabine chemotherapy. RECIST criteria 1.1 standard was adopted to evaluate effective of chemotherapy and National Cancer Institute Common Toxicity Criteria 4.0.(NCI-CTCA) was adopted to evaluate toxic reaction. Results Effective rate, median progression-free survival and overall survival of the gemcitabine combined with Tegafur Gimeracil Oteracil Potassium group were all higher than those of the gemcitabine group. Incidences of myelosuppression, gastrointestinal reaction, oral mucositis and fatigue in the combined chemotherapy group were higher than those of the single group. There were mainly toxic reactions of I-II grade. Conclusion Gemcitabine combined with Tegafur Gimeracil Oteracil Potassium third-line in treatment of advanced non-small cell lung cancer has better effect than single gemcitabine. It has good tolerance and it can be regarded as a choice of third-line treatment of advanced non-small cell lung cancer.更多还原